ArticlePloS one2025
Curcumin attenuates LPS-induced inflammation in RAW 264.7 cells: A multifaceted study integrating network pharmacology, molecular docking, molecular dynamics simulation, and experimental validation.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The potential of plant-derived exosome-like nanovesicles fromFuture science OA · 2026Article
- The JAK/STAT pathway: a pivotal therapeutic target in disease and advances in natural product modulation.Molecular diversity · 2026Review
- Combined Anti-Inflammatory Effects of Curcumin and Evodiamine: In Vitro Synergy, Docking, and Molecular Orbital Insights.International journal of molecular sciences · 2026Article
- Preventing relapse in ulcerative colitis remission maintenance: machine learning prediction and reinforcement-learning herbal prescription optimization with external validation.Frontiers in medicine · 2026Article
- Integrating network pharmacology, molecular docking and dynamics simulation to decipher the antipyretic mechanisms of Xiaochaihu granules.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation is a critical immune response that protects the body from infections and injuries. However, chronic inflammation can lead to diseases such as cancer. Curcumin, a bioactive compound extracted from Curcuma longa, has been widely studied for its anti-inflammatory properties. Despite extensive research, the comprehensive molecular mechanisms underlying curcumin's anti-inflammatory effects, particularly its multi-target regulatory network, remain incompletely understood. This study aims to elucidate these mechanisms using an integrated approach combining network pharmacology, molecular docking, molecular dynamics simulation, and in vitro experimental validation.
methodsWe utilized network pharmacology to identify potential targets and pathways involved in curcumin's anti-inflammatory effects. Molecular docking and dynamics simulation were conducted to evaluate the binding affinity and stability of curcumin with key inflammatory targets. The anti-inflammatory effects of curcumin were further validated in vitro using LPS-induced RAW 264.7 cells. Cell viability, NO content, and mRNA expression levels of pro-inflammatory cytokines (IL-1β, IL-6, and TNF) were assessed.
resultsNetwork pharmacology identified 135 potential targets for curcumin's anti-inflammatory effects, with key pathways including TNF, HIF-1, PI3K-Akt, JAK-STAT, and MAPK signaling pathways. Molecular docking revealed strong binding affinities of curcumin with core targets such as IL-6, TNF, IL-1β, AKT1, and STAT3, with binding energies ranging from -6.2 to -7.5 kcal/mol. Molecular dynamics simulations demonstrated the stability of these complexes over a 100-nanosecond period. In vitro experiments showed that curcumin significantly reduced NO production and mRNA expression of IL-1β, IL-6, and TNF in LPS-induced RAW 264.7 cells, with optimal effects observed at a concentration of 125 μg/mL.
conclusionOur study provides a comprehensive understanding of curcumin's anti-inflammatory mechanisms through an integrated approach. The findings highlight curcumin's potential as a therapeutic agent for inflammatory diseases. However, further in vivo studies are necessary to fully elucidate its therapeutic efficacy and mechanisms of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.